Artelo Biosciences Secures $11 Million in New Funding for Corporate Growth and Debt Reduction

Artelo Biosciences Announces New Funding Round

In a recent corporate development, Artelo Biosciences has successfully closed a private funding round, securing $11 million in new capital. The transaction involved the sale of common shares priced at $3.45 per share, with a total of 3,188,407 shares placed.

Allocation of Funds and Strategic Focus

Company leadership outlined that the freshly acquired capital will be directed toward two primary objectives: supporting ongoing corporate operations and repaying a portion of interim debt. This move is designed to strengthen the company's financial footing and provide a more stable platform for future initiatives.

• Operational Support: Ensuring continued progress in research pipelines
• Debt Management: Reducing financial overhead and improving capital efficiency

As a player in the biotechnology sector, this infusion of funds positions Artelo Biosciences to maintain its growth trajectory in a dynamic market. The positive investor response to this private placement underscores confidence in the company's strategic direction.